

# Competitor Analysis: CD20 Antibodies 2015 - Biosimilars and Biosuperiors of Rituximab

<https://marketpublishers.com/r/CC2255ED973EN.html>

Date: March 2015

Pages: 62

Price: US\$ 346.00 (Single User License)

ID: CC2255ED973EN

## Abstracts

Competitor Analysis: CD20 Antibodies 2015 - Biosimilars and Biosuperiors of Rituximab

This Competitive Intelligence Report about CD20 Antibodies 2015- Biosimilars and Biosuperiors of Rituximab provides a competitor evaluation in the field of recombinant antibodies targeting CD20 for treatment of B-cell mediated malignancies and rheumatoid arthritis as of March 2015. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.

The chimeric anti-CD20 antibody rituximab (Rituxan / MabThera) from Biogen Idec and Roche is one of the world's commercially most successful antibodies (2014 sales of over US\$ 6.9 bln). The commercial attractiveness of rituximab has stimulated companies to create and develop next generation anti-CD20 monoclonal antibodies with improved properties compared with the chimeric antibody rituximab. The forthcoming patent expiry for Rituxan / MabThera has boosted interest in and activities for developing biosimilar copies with the most advanced projects already approved and marketed in less regulated countries, but also in phase III studies in Western regulated markets.

The report includes a compilation of currently active projects in development of CD20 targeting antibodies for treatment of hematologic malignancies and rheumatoid arthritis and other autoimmune diseases. In addition, the report lists company-specific R&D pipelines of CD20 antibodies. Competitor projects are listed in a tabular format providing information on:

Drug Codes,

Target / Mechanism of Action,

Class of Compound,

Company,

Product Category,

Indication,

R&D Stage and

additional comments with a hyperlink leading to the source of information.

#### About Competitor Analysis Series:

The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.

## Contents

### **1. CD20 Antibodies 2015 - Biosimilars and Biosuperiors of Rituximab**

#### **2014 Sales of CD20 Antibodies**

#### **Marketed CD20 Antibodies & Sales**

Rituxan/MabThera Pipeline & Sales

Gazyva/ Gazyvaro Pipeline & Sales

Arzerra Pipeline & Sales

Zevalin Pipeline & Sales

#### **Biosuperior CD20 Antibodies**

#### **Biosimilar CD20 Antibodies**

Rituxan/MabThera (rituximab) Biosimilars

### **2. Corporate CD20 Antibody Biosimilar & Biosuperior Pipelines**

## I would like to order

Product name: Competitor Analysis: CD20 Antibodies 2015 - Biosimilars and Biosuperiors of Rituximab

Product link: <https://marketpublishers.com/r/CC2255ED973EN.html>

Price: US\$ 346.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CC2255ED973EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970